PDSA is dedicated to enhancing the lives of patients with immune thrombocytopenia (ITP) and other platelet disorders through education, advocacy, research and support.In 2016, PDSA established with the goal of funding the most promising research that have the potential to raise an ITP patient’s quality of life by further understanding the pathogenesis and management of primary ITP to support development of new therapies and a cure. PDSA invites the research community to submit proposals for grants that will help us meet these goals.
Research must be focused on primary ITP. Clinically oriented, observational, and laboratory hypothesis-driven research proposals related to ITP are encouraged. Proposals should include a clear description of a hypothesis-driven investigation that addresses an area of need in the understanding of, or treatment of primary ITP. The research plan must include evidence of consultation with and/or collaboration with patients with primary ITP (alternatively, PDSA’s Patient Research Panel). Funding may be allocated to hypothesis-driven research projects showing research for a patient benefit, according to the Patient-Centered Outcomes Research Institute (PCORI) Methodology Report, across the following areas:
- Disease incidence, prevalence, burden, causes, prevention, and management
- Gaps in evidence in terms of biomarkers, clinical outcomes, practice variation, and health disparities
- Potential for new evidence to improve health, well-being, and quality of care, such as patient qualitative studies to clarify symptoms or other quality of life issues of living with ITP
- Patient needs, outcomes, and preferences
- Relevance to patients and clinicians in making informed health decisions
The Barbara and Peter T. Pruitt Jr. ITP Research Award
Two $20,000 grants awarded annually to investigators conducting innovative ITP patient-centered research, The Barbara and Peter T. Pruitt Jr. ITP Research Award is named in honor of two generous friends and the largest single donors in the history of PDSA: Barbara Pruitt, ITP patient since age four, dedicated volunteer and passionate patient advocate and Peter Pruitt, devoted caregiver and supporter serving as PDSA’s Board Chair for over a decade.
Application Forms:
New Request for Proposals
Request for Proposals announcement provided by the Platelet Disorder Support Association for funding consideration for the research of Immune Thrombocytopenia.
Additional Funding Request for Proposals
For researchers who have previously received a PDSA Barbara and Peter T. Pruitt , Jr. ITP research grant and wish to apply for additional funding; either for a new project, or a continuation of the initial project for which funding was awarded.
Proposal Template
Budget Template
Recipients of the Barbara and Peter T. Pruitt Jr. ITP Research Award:
2023 Awards
Project Title: Immune Profiling Patients with Primary ITP Using the NanoString nCounter Platform
Investigator: Sandhya R. Panch, MD, MPH
Institution: University of Washington, Fred Hutchinson Cancer Center
Project Title: Adolescents and Young Adults with ITP – AYAS 4/5
Investigator: Alexandra Schifferli, MD
Institution: Switzerland, University Children’s Hospital Basel
2022 Awards
Project Title: Heavy Menstrual Bleeding and its Effect on Quality of Life in Adolescent Girls with Immune Thrombocytopenia
Investigator: Megan C. Brown MD, MSc
Institution: Emory University and Children’s Healthcare of Atlanta (Atlanta, GA)
Project Title: Centering Youth Voices and Experiences: Improving the Quality of Life Among Adolescent Patients Living with Chronic Immune Thrombocytopenia
Investigator: Maria De Jesus, PhD
Institution: American University (Washington, DC)
2021 Awards
Project Title: Evaluating the Prevalence of Primary Immunodeficiency in Immune Thrombocytopenia
Investigator: Sioban Keel, MD
Institution: University of Washington (Seattle)
Project Title: Deepening Into the Physiopathology and Stratification of Immune Thrombocytopenia (ITP) for More Rigorous Diagnosis, Prognosis, and Personalized Treatment Strategies
Investigator: Andrea Acebes-Huerta, PhD
Institution: Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Spain
Project Title: Adolescents and Young Adults with Immune Thrombocytopenia: Towards New Strategies – A Project of the Carmen, OBS’Cerevance, and Parc-ITP Registry
Investigator: Alexandra Schifferli, MD
Institution: Universitäts-Kinderspital beider Basel (UKBB), Basel
2020 Awards
Project Title: Role of Platelet Glycosylation on Platelet Function and Immune Response in Immune Thrombocytopenia Patient
Investigator: Nora Butta, MD
Institution: Hospital Universitario La-Paz
Project Title: Real world effectiveness of second-line therapies for primary immune thrombocytopenia (ITP): a retrospective analysis of healthcare claims data
Investigator: Karen L. Rascati, RPh, PhD
Institution: The University of Texas at Austin
2019 Awards
Project Title: Association of Platelet Parameters and Subpopulations Identified by High Dimensional Mass Cytometric Analysis of Platelets with Bleeding Severity in Pediatric patients with Immune Thrombocytopenia
Investigator: A.L. “Larry” Frelinger III, Ph.D.
Institution: Boston Children’s Hospital
Project Title: Development of New Diagnostic Tests to Categorize Different Subtypes of Immune Thrombocytopenia (ITP)
Investigator: Ishac Nazy, Ph.D.
Institution: McMaster University
Project Title: Role of Platelet Glycosylation on Platelet Function and Immune Response in Immune Thrombocytopenia Patients
Investigator: Nora Butta, MD
Institution: Hospital Universitario La-Paz
2018 Awards
Project Title: The Role of the Gut Microbiome in the Pathogenesis of ITP
Investigator: Joseph Oved, MD
Institution: The Children’s Hospital of Philadelphia
Project Title: Decision Aid to Support Shared Decision Making in Pediatric Refractory Immune Thrombocytopenia
Investigator: Cindy Neunert, MD, MSCS
Institution: Columbia University Medical Center
2017 Awards
Project Title: RNA Expression in Acute and Chronic Immune Thrombocytopenia
Investigator: Taylor Olmsted Kim, MD
Institution: Baylor College of Medicine and Texas Children’s Hospital
Project Title: Emergency Management of Severe Thrombocytopenia and Bleeding in Patients with ITP
Investigators: Siraj Mithoowani, MD, FRCP(C) and Donald Arnold, MD, MSc, FRCP(C)
Institution: McMaster University
The James B. Bussel, MD, ITP Young Investigator Award
The James B. Bussel, MD ITP Young Investigator Award was established in 2017 by the PDSA Board of Directors to honor Dr. Bussel for all that he has done and continues to do to make a difference in the lives of ITP patients, their families, and his contributions to mentoring and advancing the scientific careers of promising clinical investigators.
Fellow PDSA medical advisor Doug Cines, MD, said Dr. Bussel “was a pioneer, not only of research in ITP, but for a generation of trainees who could follow his experience. His career shows that is possible to succeed scientifically and academically as a clinically oriented investigator even in rare diseases like ITP if you are persistent and have a creative mind. There are many young investigators and countless patients with ITP who have not met Jim personally and have no idea how much they owe to his contributions to research and patient care.”
The James B. Bussel, MD, ITP Young Investigator Award is competitively awarded to support excellence in academic ITP research by providing a selected student deemed to be of exceptional promise and a highly meritorious project with a $10,000 scholarship award funded by the Platelet Disorder Support Association.
Application Form:
Request for Proposals
Request for Proposals announcement provided by the Platelet Disorder Support Association for funding consideration for the research of Immune Thrombocytopenia.
Research Program: Take Action to Make a Difference
Although more is known about ITP each year and new treatments are becoming available, there are many unanswered questions. The Platelet Disorder Support Association has established a research program to support initiatives that lead to better outcomes for the people we serve.
Contribute to our research program on-line or send a check or credit card number to:
PDSA Research Program
8751 Brecksville Road, Suite 150
Cleveland, Ohio 44141
(All contributions to our research program are tax deductible.)
GIVE NOW
Quality of Life Surveys/Studies:
ITP Patient Assessment Questionnaire (ITP-PAQ)
In 2006, PDSA partnered with the biotechnology company Amgen in the development of the Immune Thrombocytopenic Purpura Patient Assessment Questionnaire (ITP-PAQ) because no validated disease-specific measures were available to assess health-related quality of life (HRQoL) in adult subjects with ITP. The ITP-PAQ is a 44-item questionnaire that includes scales for physical health (symptoms, fatigue/sleep, bother, and activity), emotional health (psychological and fear), overall QoL, social activity, women's reproductive health, and work.
Amgen has the exclusive copyright to the ITP PAQ but has granted PDSA license to sublease the Questionnaire.
For limited, non-exclusive licenses or more information, contact Brenda Foster @ bfoster@pdsa.org.
- Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey
- Impact of corticosteroid-related symptoms in patients with immune thrombocytopenic purpura: results of a survey of 985 patients
- Impact of ITP on physician visits and workplace productivity
- ISPOR Poster presentation on workplace productivity
ITP Natural History Study Registry
The ITP Natural History Study Registry is an international patient-consented registry of individuals with ITP. The registry aims to collect, store and retrieve data on the natural progression of ITP, enabling collection of data on diagnosis and treatment, management of care, quality of life, clinician reporting, and characterization of the ITP population as a whole.
Research Findings
PDSA attends major research conferences on thrombocytopenia and monitors scientific journals to report the latest research findings in the quarterly Publication and monthly e-News.
Clinical Trials
PDSA tracks and lists the latest Clinical Trials on ITP to assure that those who want to participate are aware of these opportunities.